Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Greaves, Ronda / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter


IMPACT FACTOR 2018: 3.638

CiteScore 2018: 2.44

SCImago Journal Rank (SJR) 2018: 1.191
Source Normalized Impact per Paper (SNIP) 2018: 1.205

Online
ISSN
1437-4331
See all formats and pricing
More options …
Volume 37, Issue 3

Issues

Supplemental Immune Globulins in Sepsis

Karl Werdan
Published Online: 2005-06-01 | DOI: https://doi.org/10.1515/CCLM.1999.057

Abstract

Intravenous immune globulins are widely used as supplemental treatment of sepsis, septic shock and systemic inflammation in the critically ill, although this indication has at best been validated in part. Likely beneficial mechanisms of action may include the improvement of serum bactericidal activity due to neutralizing and opsonizing immunoglobulin (Ig)G- and IgM-antibodies, as well as stimulation of phagocytosis and neutralization of bacterial endo- and exotoxins; another attractive mode of action may represent immune globulin-mediated modification and specific suppression of proinflammatory cytokine release from endotoxin- and superantigen-activated blood cells. For the “entire group of patients with sepsis and septic shock” a reduction in mortality by intravenous immune globulin could not be documented; however, in the score-based immunoglobulin in sepsis (SBITS)-study with 653 patients included, a moderate improvement in sepsis morbidity and multiple organ dysfunction syndrome was demonstrated. In defined sepsis subgroups, a reduction in mortality by intravenous immune globulin has been seen in individual small, not yet confirmed trials. Finally, the incidence of some severe infections in well characterized “patients at risk” and “operations at risk” is reduced by intravenous immune globulin prophylaxis. Thus, intravenous immune globulin is not a “magic bullet” of sepsis treatment, but it may reduce morbidity and thereby represent a useful piece of stone in the therapeutic mosaic of sepsis treatment.

About the article

Published Online: 2005-06-01

Published in Print: 1999-03-01


Citation Information: Clinical Chemistry and Laboratory Medicine, Volume 37, Issue 3, Pages 341–349, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/CCLM.1999.057.

Export Citation

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Kevin B. Laupland, Andrew W. Kirkpatrick, and Anthony Delaney
Critical Care Medicine, 2007, Volume 35, Number 12, Page 2686
[2]
A Sablotzki, J Mühling, M G Dehne, B Zickmann, R E Silber, and I Friedrich
Perfusion, 2001, Volume 16, Number 2, Page 113
[3]
Michiko Aoyama-Ishikawa, Ayumi Seishu, Saori Kawakami, Noriaki Maeshige, Makoto Miyoshi, Takahiro Ueda, Makoto Usami, Atsunori Nakao, and Joji Kotani
Surgical Infections, 2014, Volume 15, Number 1, Page 36
[4]
Giorgio Berlot, Michele C. Vassallo, Nicola Busetto, Monica Bianchi, Francesca Zornada, Ivana Rosato, Fabiana Tartamella, Lara Prisco, Federica Bigotto, Tiziana Bigolin, Massimo Ferluga, Irene Batticci, Enrico Michelone, Massimo Borelli, Marino Viviani, and Ariella Tomasini
Journal of Critical Care, 2012, Volume 27, Number 2, Page 167
[5]
Marco Sifringer and Claudia D. Spies
Critical Care Medicine, 2012, Volume 40, Number 4, Page 1368
[6]
A.O. Ian Gust
Biologicals, 2012, Volume 40, Number 3, Page 196
[7]
Christian Gille, Stephan Dreschers, Bärbel Spring, Attila Tárnok, Jozsef Bocsi, Christian F. Poets, and Thorsten W. Orlikowsky
Cytometry Part B: Clinical Cytometry, 2012, Volume 82B, Number 1, Page 26
[8]
Bernd G. Stegmayr, Ravjet Banga, Lars Berggren, Rut Norda, Anders Rydvall, and Tomas Vikerfors
Critical Care Medicine, 2003, Volume 31, Number 6, Page 1730
[9]
A. G. Tsiotou and G. H. Sakorafas
European Journal of Anaesthesiology, 2004, Volume 21, Number 5, Page 337
[10]
[11]
Kevin B. Laupland, Andrew W. Kirkpatrick, and Anthony Delaney
Critical Care Medicine, 2007, Volume 35, Number 12, Page 2686
[12]
Oscar Arrieta, Tatiana Sofia Rodriguez-Reyna, and Julio Sotelo
Expert Opinion on Therapeutic Patents, 2000, Volume 10, Number 5, Page 601
[13]
Satoshi Hagiwara, Hideo Iwasaka, Akira Hasegawa, Nobuhiko Asai, and Takayuki Noguchi
Intensive Care Medicine, 2008, Volume 34, Number 10, Page 1812
[14]
Charles F. Bolton and G. Bryan Young
Current Treatment Options in Neurology, 2000, Volume 2, Number 6, Page 489
[15]
Karl Werdan
Current Opinion in Critical Care, 2001, Volume 7, Number 5, Page 354
[16]
Sreenandh Krishnagopalan and R. Phillip Dellinger
BioDrugs, 2001, Volume 15, Number 10, Page 645

Comments (0)

Please log in or register to comment.
Log in